« Previous AbstractBiomarkers of therapy responsiveness in asthma: pitfalls and promises    Next AbstractInflammatory phenotypes underlying uncontrolled childhood asthma despite inhaled corticosteroid treatment: rationale and design of the PACMAN2 study »

Biologics

Title:		Clinical utility of asthma biomarkers: from bench to bedside
Author(s):		Vijverberg SJ; Hilvering B; Raaijmakers JA; Lammers JW; Maitland-van der Zee AH; Koenderman L;
Address:		"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands ; Department of Respiratory Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands"
Journal Title:		Biologics
Year:		2013
Volume:		20130829
Issue:
Page Number:		199 - 210
DOI:		10.2147/BTT.S29976
ISSN/ISBN:		1177-5475 (Print) 1177-5491 (Electronic) 1177-5475 (Linking)
Abstract:		"Asthma is a chronic disease characterized by airway inflammation, bronchial hyperresponsiveness, and recurrent episodes of reversible airway obstruction. The disease is very heterogeneous in onset, course, and response to treatment, and seems to encompass a broad collection of heterogeneous disease subtypes with different underlying pathophysiological mechanisms. There is a strong need for easily interpreted clinical biomarkers to assess the nature and severity of the disease. Currently available biomarkers for clinical practice - for example markers in bronchial lavage, bronchial biopsies, sputum, or fraction of exhaled nitric oxide (FeNO) - are limited due to invasiveness or lack of specificity. The assessment of markers in peripheral blood might be a good alternative to study airway inflammation more specifically, compared to FeNO, and in a less invasive manner, compared to bronchoalveolar lavage, biopsies, or sputum induction. In addition, promising novel biomarkers are discovered in the field of breath metabolomics (eg, volatile organic compounds) and (pharmaco)genomics. Biomarker research in asthma is increasingly shifting from the assessment of the value of single biomarkers to multidimensional approaches in which the clinical value of a combination of various markers is studied. This could eventually lead to the development of a clinically applicable algorithm composed of various markers and clinical features to phenotype asthma and improve diagnosis and asthma management"
Keywords:		airway inflammation asthma biological markers metabolomics pharmacogenomics;
Notes:		"PubMed-not-MEDLINEVijverberg, Susanne Jh Hilvering, Bart Raaijmakers, Jan Am Lammers, Jan-Willem J Maitland-van der Zee, Anke-Hilse Koenderman, Leo eng Review New Zealand 2013/09/07 Biologics. 2013; 7:199-210. doi: 10.2147/BTT.S29976. Epub 2013 Aug 29"